Nieuws

MedPage Today52 m
'Armored' CAR T Cells Highly Active in Lymphoma After Prior CAR-T Failure
A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...